10,000 volunteers: Novavax coronavirus vaccine enters late stage trials in UK
Up to 10,000 volunteers aged between 18 and 84 will be enrolled for the study, which is set to take place over the next four to six weeks and marks the final step of the regulatory approvals process.
Half of the volunteers will receive two shots of NVX-CoV2373 with Matrix-M, Novavax's adjuvant, which is meant to strengthen the vaccine. The other participants will be given a placebo. ■